Publications

• Comment on: development and external validation of a model to predict overall survival in patients with resected gallbladder cancer.

  (Chakrabarti S, Mahipal A.) Hepatobiliary Surg Nutr. 2022 Feb;11(1):136-138 PMID: 35284516 PMCID: PMC8847856 03/15/2022

• Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.

  (Chakrabarti S, Finnes HD, Mahipal A.) Expert Opin Drug Metab Toxicol. 2022 Jan;18(1):85-98 PMID: 35129006 02/08/2022

• Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma.

  (Kamgar M, Chakrabarti S, Shreenivas A, George B.) Surg Oncol Clin N Am. 2021 10;30(4):673-691 PMID: 34511189 SCOPUS ID: 2-s2.0-85111041414 09/14/2021

• TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies.

  (Chakrabarti S, Wintheiser G, Tella SH, Oxencis C, Mahipal A.) Pharmacol Ther. 2021 08;224:107823 PMID: 33667525 SCOPUS ID: 2-s2.0-85102047484 03/06/2021

• Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma.

  (Kankeu Fonkoua LA, Chakrabarti S, Sonbol MB, Kasi PM, Starr JS, Liu AJ, Nevala WK, Maus RL, Bois MC, Pitot HC, Chandrasekharan C, Ross HJ, Wu TT, Graham RP, Villasboas JC, Weiss M, Foster NR, Markovic SN, Dong H, Yoon HH.) Int J Cancer. 2021 07 15;149(2):378-386 PMID: 33739449 PMCID: PMC8488901 03/20/2021

• A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy.

  (Cox RE Jr, Mahipal A, Chakrabarti S.) Cureus. 2021 Apr 22;13(4):e14640 PMID: 34055508 PMCID: PMC8144075 06/01/2021

• Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

  (Sinicrope FA, Chakrabarti S, Laurent-Puig P, Huebner L, Smyrk TC, Tabernero J, Mini E, Goldberg RM, Zaanan A, Folprecht G, Van Laethem JL, Le Malicot K, Shi Q, Alberts SR, Taieb J.) Eur J Cancer. 2021 02;144:101-112 PMID: 33341444 PMCID: PMC7855426 12/21/2020

• The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review.

  (Chakrabarti S, Xie H, Urrutia R, Mahipal A.) Cancers (Basel). 2020 09 29;12(10) PMID: 33003583 PMCID: PMC7601010 10/03/2020

• Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions.

  (Chakrabarti S, Peterson CY, Sriram D, Mahipal A.) World J Gastrointest Oncol. 2020 Aug 15;12(8):808-832 PMID: 32879661 PMCID: PMC7443846 09/04/2020

• Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm.

  (Chakrabarti S, Kamgar M, Mahipal A.) Cancers (Basel). 2020 Jul 24;12(8) PMID: 32722188 PMCID: PMC7465131 07/30/2020

• Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management

  (Sakti Chakrabarti, Heidi D. Finnes, Amit Mahipal.) Expert Opinion on Drug Metabolism & Toxicology . Published online: 12 Feb 2022 02/12/2022

• Comment on: development and external validation of a model to predict overall survival in patients with resected gallbladder cancer

  (Sakti Chakrabarti, Amit Mahipal..) HepatoBiliary Surgery and Nutrition. . doi: 10.21037/hbsn-21-514 12/13/2021